Jan Stern Reed - 03 Jun 2026 Form 4 Insider Report for AVITA Medical, Inc. (RCEL)

Reporting relationship: Director
Issuer ticker: RCEL
Reported as of: 03 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jun 2026, 19:08:18 UTC
Prior SEC filing: 13 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Nicole Kelsey, by power of attorney

Key filing fact

Jan Stern Reed filed Form 4 for AVITA Medical, Inc. (RCEL) on 04 Jun 2026.

Key facts

This page summarizes Jan Stern Reed's Form 4 filing for AVITA Medical, Inc. (RCEL).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Jun 2026, 19:08.

Change

Previous filing in this sequence was filed on 13 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001124181 Primary reporting owner

REED JAN STERN

Relationship: Director
Address: C/O AVITA MEDICAL 28159 AVENUE STANFORD, SUITE 220 - AVITA MEDICAL, VALENCIA
Signature: /s/ Nicole Kelsey, by power of attorney
Signature date: 04 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCEL transaction

Common Stock

Award

Transaction value
Shares: +22,214
Change %: +44%
Price
Shares after: 73,225
Date: 20 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCEL transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +16,133
Change %
Price: $0.000000^*
Shares after: 16,133
Date: 20 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,133
Exercise price: $3.77
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

Footnote F2

Includes unvested RSUs.

Footnote F3

On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.